Palvella Therapeutics will host a conference call on February 24, 2026, at 8:00 a.m. ET to discuss topline results from its Phase 3 SELVA clinical trial evaluating QTORIN 3.9% rapamycin anhydrous gel as a treatment for microcystic lymphatic malformations. The company will release the trial data at 6:30 a.m. ET, preceding the investor call by 90 minutes.
Microcystic lymphatic malformations are rare vascular anomalies characterized by abnormal lymphatic vessel development. QTORIN represents a potential therapeutic option for this challenging-to-treat condition, with the Phase 3 SELVA trial serving as a pivotal study to support regulatory review. The timing of the results disclosure and subsequent management discussion will provide investors and healthcare professionals with detailed efficacy and safety data from the late-stage trial.
The presentation of these results marks a significant milestone for the company's clinical program and may influence future regulatory pathways and commercial development strategies for the candidate therapy.